Medical Device Registration in Japan: How Should Multiple Models Be Grouped in a Filing?

Medical Device Registration in Japan: How Should Multiple Models Be Grouped in a Filing?

Published: 15 July 2026 19:49  |  Updated: 15 July 2026 19:49

To group multiple models of a medical device into a single Japanese registration filing, a manufacturer should first confirm the target country, the product risk class, the applicable regulatory pathway and the existing documentation base, and only then assess the technical file, quality management system, labelling and instructions for use, local representative arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission so that unclear classification, incomplete evidence or unresolved authorization arrangements do not extend the project timeline. For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Registration in a target market typically affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change control at the same time; if a project is driven only by the question of which documents to submit, deficiencies and rework are likely to appear in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends positioning this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than rebuilding documentation on an ad hoc basis for each country.

Compiled from the AIMEILI registration practice question bank, the medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product's documentation base.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI's Perspective
• Frequently Asked Follow-up Questions
• Further Reading
• Scope of Applicability

Key Summary

On the question of how multiple models of a medical device should be grouped in a Japanese registration filing, companies should first confirm the target country, the product risk class, the applicable regulatory pathway and the existing documentation base, and then evaluate the technical file, quality management system, labelling and instructions for use, local representative, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid a prolonged project cycle caused by unclear classification, documentation or authorization arrangements.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Registration in a target market usually affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If the project is advanced only on the basis of which documents to submit, deficiencies or rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends planning this question together with a GHWP member state and multi-country market access strategy, using one set of reusable core technical documentation to support localization in different markets rather than rebuilding documentation on a temporary basis for each country.

Applicable Scenarios and Core Questions

Companies searching for how multiple models should be grouped in a Japanese registration filing are usually not looking for a conceptual explanation. They need to judge whether their existing documentation can support a submission in the target market, whether a local representative or authorized representative is required, why the timeline has been extended, and which issues may affect the launch plan. Behind this question there are typically several interrelated elements: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for one country alone is not sufficient. A more valuable approach is to first turn the core technical file, quality system evidence, performance verification, clinical evidence and labelling and instructions for use into reusable versions, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

A company should first confirm the intended use, mechanism of action, use scenario, method and duration of body contact, whether the device is sterile, whether it is powered, and whether it contains software or has IVD characteristics, and then determine the risk class and the submission pathway. Once the pathway is judged incorrectly, downstream translation, notarization, authorization, testing and supplementary documentation will all move in the wrong direction.

For a target market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains the documentation for certificate renewal. If these points are handled only vaguely in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Label and IFU claims, the models covered by test reports, the scope of application of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents a company has uploaded.

Common Errors

The most common problem is that a company treats a registration project as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting a direct translation of domestic NMPA documentation without restructuring the evidence according to the target market pathway.
• Having too many model and specification variants while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local representative purely as a sales partner, without defining regulatory responsibility, certificate control and post-market maintenance duties.
• Inconsistency between labels, instructions for use, promotional materials and registration documentation, resulting in deficiency notices or post-market compliance risk.
• Failure to plan multi-country documentation reuse in advance, causing repeated preparation in each country and inflating both cost and timeline.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base and avoid discovering critical evidence gaps only after submission has begun.

• Compile the target product list, model and specification matrix, and intended use statement.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local representative or authorized representative.
• Establish a gap assessment table for the target country, specifying what must be re-tested, translated, notarized or covered by supplementary declarations.

AIMEILI's Perspective

AIMEILI recommends that companies not treat target market registration as a one-off document submission, but manage it as an overseas market access project. For companies preparing to enter several countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable and more conducive to later changes and certificate renewals than supplementing documentation on a country-by-country basis.

From a project management perspective, three things should be controlled in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three points are unclear, the project may still encounter repeated cycles of deficiency responses, agent communication and post-market maintenance, no matter how extensive the documentation appears.

Frequently Asked Follow-up Questions

Can domestic documentation be used directly for target market registration?

Domestic documentation can serve as a basis, but it generally cannot be submitted as-is. Companies need to adjust the documentation structure, language, labelling, authorization documents and evidence chain in accordance with local regulatory requirements.

When is the best time to start the gap assessment?

The assessment should ideally start immediately after the target market and product list are confirmed. The earlier the gap assessment is completed, the easier it is to arrange supplementary testing, translation, label adjustments and representative selection in advance.

Why does the choice of local representative affect registration quality?

The local representative is usually involved in registration communication, changes, certificate renewal and the handling of post-market incidents. Unclear allocation of rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, model and specification details, registration pathway, documentation owners, translation status, testing status, local representative communication records and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management judge whether the project will affect the launch plan.

Companies that already have registration bases in several countries should also build an evidence reuse matrix that clarifies which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates in particular must be kept at consistent versions.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local representative and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality Management System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent. If the scope covered by the ISO 13485 certificate does not match the products being registered, or if the manufacturing site, model specifications, IFU version and test reports are inconsistent, a company may be asked for supplementary explanations even after preparing a large volume of documents.

Before submission, companies should build an evidence consistency checklist that maps the product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version and quality system certificate item by item. This step appears basic, but it can significantly reduce the probability of deficiency notices, particularly for projects covering several GHWP member states or several product families submitted at the same time.

Localization Conversion and Representative Responsibility

Target market registration projects usually involve arrangements with a local representative, authorized representative, importer or registration holder. Companies must confirm in advance whether the local partner is responsible only for submitting documentation, or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, instructions for use and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable in the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean that compliance work is finished. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance; once a manufacturing site change, model expansion, IFU update or representative replacement occurs, the certificate and the marketed product can easily become misaligned.

AIMEILI recommends managing this question within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only greater efficiency in a single country's registration; more importantly, it enables companies to develop a replicable overseas compliance capability and reduce the cost of starting documentation from scratch each time they enter a new market.

Further Reading

• Previous article: What Should Be Prepared Before Renewing a Medical Device Registration in Japan?
• Next article: What Are the Requirements for a Risk Management File in Japanese Medical Device Registration?
• Recommended reading: How Should a Local Representative Be Selected for Medical Device Registration in Brazil?
• Recommended reading: How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Recommended reading: Why Is the Registration Timeline Extended for Medical Device Registration in Brazil?
• Recommended reading: What Are the Common Reasons for Deficiency Notices in Medical Device Registration in Brazil?
• Recommended reading: How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• Recommended reading: When Must a Change Be Filed for Medical Device Registration in Brazil?
• Back to the FAQ Center | News | Contact AIMEILI

Content Review and Scope of Applicability

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of applicability: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.